Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics

Area of Science:

• Pharmacology
• Drug Metabolism
• Reproductive Endocrinology

Background:

• Thalidomide is used for various conditions, and its drug interactions are crucial.
• Hormonal contraceptives containing ethinyl estradiol and norethindrone are widely used.
• Understanding potential interactions between thalidomide and oral contraceptives is important for patient safety.

Purpose of the Study:

• To characterize the single- and multiple-dose pharmacokinetics of oral thalidomide.
• To evaluate the impact of steady-state thalidomide on the pharmacokinetics of ethinyl estradiol and norethindrone.

Main Methods:

• A randomized, 2-period crossover study in 10 healthy premenopausal female volunteers.
• Pharmacokinetic profiles analyzed using noncompartmental and compartmental methods.
• ANOVA model used to assess the effects of thalidomide on ethinyl estradiol and norethindrone pharmacokinetics.

Main Results:

• Thalidomide pharmacokinetics were similar after single and multiple (18-day) doses.
• Thalidomide did not significantly alter the pharmacokinetic profiles of ethinyl estradiol or norethindrone.
• A minor decrease in ethinyl estradiol elimination rate constant was observed, but without affecting clearance or half-life.

Conclusions:

• Multiple-dose thalidomide pharmacokinetics mirror single-dose behavior.
• Thalidomide is unlikely to significantly affect the pharmacokinetics of orally administered hormonal contraceptives.
• Further studies are needed to confirm efficacy of combined regimens.